Analgesic Efficacy of Different Nerve Blocks in Postoperative Cesarean Section

Post Operative Pain Clinical Trial

Official title:

Analgesic Efficacy of Erector Spinae Block , Quadratus Lumborum Block and Intrathecal Morphine for Post Operative Pain Relief After Cesarean Section, A Prospective Randomized Single-Blind Controlled Study

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06088420
• Other study ID #: 17101962
• Status: Recruiting
• Phase: N/A
• Start date: October 2023
• Est. completion date: March 2025

Study information

• Verified date: October 2023
• Source: Assiut University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

comparing analgesic efficacy of different nerve blocks on post operative cesarean sections.

Description:

Analgesic efficacy of Erector Spinae, Quadratus Lumborum and Intrathecal Morphine for post operative pain relief after cesarean section, A Prospective Randomized Single-Blind Controlled Study.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 120
• Est. completion date: March 2025
• Est. primary completion date: February 2025
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years to 40 Years

Eligibility

Inclusion Criteria:

• 18-40 years old

• more or equal 37 weeks of gestation

• ASA 1,2

• Elective cesarean delivery

Exclusion Criteria:

• Patient refusal

• inability to cooperate with or understand the study

• local infection.

• bleeding disorder

• known anaphylaxis to any drug used in the trial

• ASA physical status more than 2

• emergency operations

• chronic opioid use (opioid use in the past 3 months)

• Neurologic deficit or disorder

• contraindication to regional anesthesia.

Related Conditions & MeSH terms

• Pain, Postoperative
• Post Operative Pain

Intervention

Drug:
• intrathecal morphine for intrathecal morphine group . bupivacaine 0.25% for Quadratus Lumborum and Erector Spinae nerve block groups .
Intrathecal morphine Group: All members of this group will receive spinal anesthesia with 12 mg 0.5% (2.2ml) hyperbaric bupivicane with intrathecal morphine(100mcg). QLB Group: All members of this group will receive bilateral quadratus lumborum block after spinal anesthesia at end of operation. The QLB will be performed by using bupivacaine 0.25% .ESB Group: All members of this group will receive bilateral erector spinae block after spinal anesthesia at end of operation. The ESB will be performed by using bupivacaine 0.25% (15 ml in each side) .

Locations

Country	Name	City	State
Egypt	Mahmoud Mamdouh Ekram	Assiut	Manfalout

Sponsors (1)

Lead Sponsor	Collaborator
Assiut University

Country where clinical trial is conducted

Egypt, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Duration of analgesia until first analgesic request.	post operative pain control.	24 hours .
Secondary	onset of pain . pain intensity using Numerical Analogue Score ( NRS) . ordered from 0 to 10 . 0 value indicates no pain , 10 value indicates worst pain	post operative pain control.	more or less than 2 years